Hologic's $18.3 Billion Buyout: A New Chapter Ahead

Author: Dylan Bailey Updated: 10-21-2025 12:23 PM

Overview of the Acquisition

Hologic, Inc. (NASDAQ: HOLX) has recently announced an agreement to be acquired by investment funds managed by Blackstone Inc. (NYSE: BX) and TPG Inc. (NASDAQ: TPG). This notable buyout is valued at approximately $18.3 billion. Following this news, Hologic's shares have seen a positive response in the market.

Transaction Insights

The acquisition details reveal that the purchase price is set at $79 per share. This figure offers an impressive 46% premium compared to Hologic’s share price ahead of the announcement of the potential acquisition. Shareholders will receive $76 in cash per share, along with a contingent value right (CVR), which could yield up to an additional $3 per share through two possible payments of $1.50 each, contingent upon meeting specified revenue milestones.

For the shareholders, this CVR system incentivizes performance, as it is linked to Hologic’s Breast Health business reaching certain global revenue markers during the fiscal years 2026 and 2027. Additional investments will come from a subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate from GIC.

Board Endorsement

The acquisition has received the endorsement from the Hologic Board of Directors, which has unanimously approved the transaction. This agreement will see Hologic ceasing its operations on the Nasdaq stock exchange upon completion, signaling the end of its journey as a public entity.

Management Perspectives

Stephen P. MacMillan, Hologic’s chairman, president, and CEO, expressed confidence in the acquisition, stating, “With their resources and commitment to women’s health, Blackstone and TPG will help us drive growth and innovation in medical technologies.” His comments reflect a shared enthusiasm for the strategic advantages this partnership will bring.

John Schilling, M.D., Co-Managing Partner of TPG Capital, also commented, highlighting TPG's long-standing focus on healthcare innovation. He views Hologic as a vital opportunity for developing advanced healthcare solutions that significantly impact patient care.

Future Earnings Guidance

Looking ahead, Hologic is preparing to release its fourth-quarter fiscal 2025 results soon. However, due to the ongoing acquisition negotiations, the company has opted not to provide financial guidance for fiscal 2026 or conduct regular earnings calls during this transition period.

This acquisition could represent a pivotal moment for Hologic, aligning the company’s operations with significant investment and expertise in the healthcare sector.

Price Movements

As of the latest market check, shares of Hologic (HOLX) are up by 3.26%, trading at around $74.21. This reflects investor optimism about the future under new ownership and the anticipated advantages the buyout will foster.

Frequently Asked Questions

What is the value of Hologic's acquisition deal?

The acquisition deal is valued at approximately $18.3 billion.

Who are the companies acquiring Hologic?

Hologic is being acquired by Blackstone Inc. and TPG Inc.

What will shareholders receive as part of the acquisition?

Shareholders will receive $79 per share, comprised of $76 in cash and potential additional payments via contingent value rights.

When is the acquisition expected to close?

The transaction is anticipated to close in the first half of 2026, pending regulatory approvals and customary conditions.

How will this acquisition affect Hologic's stock trading?

Once finalized, Hologic will cease trading on the Nasdaq, ending its status as a publicly traded company.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.